Introduction {#s1}
============

Deficiency of serine/threonine kinase 4 (STK4), also referred to as mammalian sterile 20-like protein (MST1), is an autosomal recessive primary immunodeficiency (PID) typically characterized by profound CD4 lymphopenia and recurring infections ([@B1]--[@B6]). STK4 deficiency in humans leads to decreased proliferation, increased susceptibility to apoptosis and dysregulation of the transcription factor Forkhead box protein O1 (FOXO1) and its downstream targets in T cells ([@B1]--[@B3]). Leukocytes show defective adhesion and chemotaxis ([@B5]). Due to the T cell impairment, many STK4-deficient patients experience fulminant EBV infections leading to lymphoproliferation and lymphoma development ([@B1], [@B2], [@B5]). This EBV associated lymphoproliferation can be observed in various PIDs including T cell defects, e.g., in patients with mutations in the *Interleukin-2-Inducible T Cell Kinase (ITK)* gene or in the *Magnesium Transporter 1 (MAGT1)* gene ([@B7]--[@B9]). Other disorders associated with lymphoproliferation and EBV infections are X-chromosomal linked lymphoproliferative disorders (SAP deficiency, XIAP deficiency), CD27 deficiency or FAAP24 deficiency ([@B10]--[@B14]). Interestingly, a recent report showed that STK4 plays a critical role as a tumor suppressor in the development of lymphoma and leukemia ([@B15]), putting STK4 deficient patients at an even higher risk to experience malignancies. Here we report on two patients with primary immunodeficiency due to homozygous STK4 mutations that were both initially clinically diagnosed as potentially ALPS like. One of them presented with the first reported case of an EBV negative lymphoma in this patient cohort.

Materials and methods {#s2}
=====================

Patients, relatives and healthy controls
----------------------------------------

Patients, relatives and healthy controls were enrolled in this study after obtaining written informed consent. All experiments were approved by the Ethical Review Boards of the Hadassah Hebrew University, the Israeli Ministry of Health and the University Hospital Düsseldorf.

Isolation and cultivation of mononuclear cells
----------------------------------------------

Peripheral blood was obtained from the patients, relatives and healthy individuals. Mononuclear cells (PBMC) were isolated using density gradient centrifugation and cultured in medium consisting of RPMI 1640 (Life Technologies, Darmstadt, Germany) and Panserin 401 (PAN-Biotech, Aidenbach, Germany) mixed 1:1, supplemented with 10% fetal calf serum (FCS, GE Healthcare, Little Chalfont Buckinghamshire, UK) and 100 μg gentamycin (Life Technologies) and 30 U/ml IL2 (Miltenyi, Bergisch Gladbach, Germany). For the first 4 days, cells were activated by addition of 7 μg/ml phytohemaggluttinine (PHA, Life Technologies).

Transformation of primary T cells
---------------------------------

T cells from patient P1 and healthy controls were immortalized by transformation with herpes virus saimiri as decribed ([@B16]).

Whole-exome sequencing and bioinformatic analysis
-------------------------------------------------

To identify the disease causing mutations next generation sequencing was carried out after targeted enrichment of whole exonic regions from sheared genomic DNA of the patient and family members using the SeqCap EZ Exome Library 2.0 kit (Roche/Nimblegen, Madison, WI). 100 bp single-read sequencing was performed on a HiSeq2000 (Illumina, San Diego, CA). Sequencing data was aligned to the human genome assembly hg19 (GRCh37) using BWA ([@B17]). Sequencing data was converted using Samtools ([@B18]). Variation calls were obtained employing GATK, HapMap, OmniArray, and dbSNP134 datasets (The Broad Institute, Cambridge, MA). Single nucleotide variations were annotated using the Variant Effect Predictor, based on the Ensemble database (v70). Variations were imported into a proprietary MySQL database driven workbench (termed Single Nucleotide Polymorphism Database, SNuPy).

Validation of the *STK4* sequence variations
--------------------------------------------

Validation of *STK4* nucleotide variations were performed by PCR/Sanger sequencing using genomic DNA from the patients and family members. The following primers were used: *STK4* c.1103 delT (P1) forward: 5′-CCT TTT TCT AAT GCG CTG ATG-3′, reverse: 5′- ATC TTT TCC TGG GGT TCA GG-3′; *STK4* c.525+2 T\>G (P2) forward: 5′- GGA CCT GAA TAA GTG TTA AAT CTC G−3′, reverse: 5′- TAA GCC TGC ATG AAC CAT GA−3′. DNA fragments were amplified by PCR employing the Phusion High Fidelity PCR Master Mix (NEB, Ipswich, MA), 0.5 μM each primer and 20 ng of template genomic DNA. Cycling conditions: 30 s at 98°C followed by 30 cycles of 7 s at 98°C, 23 s at 60°C, 30 s at 72°C and a final extension of 10 min at 72°C. Sanger sequencing was carried out by a core facility (BMFZ, University Düsseldorf, Germany). The nucleotide variations were visualized using sequencher software (Gene Codes, Ann Arbor, MI).

Real-time PCR
-------------

cDNA preparation was carried out using the QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Quantitative Real Time PCR was performed using the QuantiFast SYBR Green PCR Kit (Qiagen) on a CFX Connect machine (Bio-Rad Laboratories GmbH, Munich, Germany) under the following conditions: an initial step of 95°C for 15 min was followed by 40 cycles of 94°C for 15 s, 55°C for 30 s, and 72°C for 30 s. For STK4, Bcl-2, IL-7RA, Foxo1, and GAPDH we used the QuantiTect Primer Assay (Qiagen, QT00068922, QT00025011, QT00053634, QT00044247, QT00079247). Expression was calculated as fold of control using the ΔΔCt method.

Immunoblotting
--------------

Cells were lysed in RIPA buffer containing 1% NP40, 50 mM Tris, pH 7.5, 350 mM NaCl, 0.5 mM EDTA, 2 mM dithiothreitol, protease- and phosphatase- inhibitor cocktail. Proteins were separated on 8.5% polyacrylamide gels, transferred to nitrocellulose membranes and detected by chemiluminescence. The following antibodies were used: STK4 (\#3682, Cell Signaling Technology, Leiden, Netherlands), β-Actin (\#A2228, Sigma-Aldrich, Taufkirchen, Germany), anti-rabbit and anti-mouse antibody (both from Cell Signaling Technology, \#7074S and \#7076S).

Cell proliferation
------------------

PBMC were treated with 7 μg/ml phytohemaggluttinine (PHA), 5 μg/ml anti-CD3 antibody (BioLegend, San Diego, USA) or 5 μg/ml tetanus toxoid (Sigma-Aldrich) and cultivated for 72 h. Radioactive uptake was quantified after 4 h priming with ^3^H-thymidine (Perkin Elmer, Rodgau, Germany). Primary T cells from patient P1, family members and healthy control were stimulated with the human T Cell Activation/Expansion Kit (Miltenyi) according to the manufacturer's protocol for up to 4 days. Every day cell count was analyzed with trypan blue (Sigma-Aldrich) solution to control cell proliferation over time.

Apotosis
--------

Activated primary or transformed T cells were stimulated with recombinant Fas ligand (Super-Fas, 50 ng/ml, Enzo Life Sciences, Loerrach, Germany) or 0.5 μM staurosporine (LC Laboratories, Woburn, MA) for 16 h or serum starved for 2 days or left untreated. Apoptosis was analyzed by flow cytometric measurement of Annexin V-FITC (BD Biosciences, Heidelberg, Germany) and propidium iodide (PI, Sigma-Aldrich) staining using a FACSCalibur equipped with CellQuest software according to the manufacturer\'s instructions (BD Biosciences).

Background {#s3}
==========

We report on two patients. Patient P1, a girl, was born to a consanguineous family of Turkish origin. She had a history of pulmonary valve stenosis, recurring otitis and polyarthritis with massively elevated rheumatoid factors. At the age of 10, she presented in our department to exclude a rheumatoid disorder. Hematological studies showed CD4 lymphopenia with a profound dysregulation of immunoglobulin levels (decreased IgG, increased IgM and IgA). In addition, sonography revealed abdominal masses in the liver and enlarged lymph nodes, which were caused by a highly malignant non-classical B cell lymphoma with intermediary characteristics of diffuse large B cell lymphoma and Burkitt\'s lymphoma. Diagnostic for infectious disease in blood, liquor and a tumor biopsy returned negative for viral DNA (including CMV, EBV, HHV6, HSV1, and HSV2) and antibody titer analysis of the serum showed no sign of an active viral infection. In addition, immune histochemical analysis of tumor material demonstrated the absence of EBV positive blasts. She was then treated according to NHL-BFM 04 protocol (risk group 2) with an additional BFM-CC block (risk group 3, dosis reduced to 80%). She responded well and achieved a complete tumor remission fast. At the age of 12, she presented again with lymphadenopathy and suspicion of relapse, but pathohistological characterization showed no malignancy at that time. Because immunoglobulin dysregulation, CD4 lymphopenia and recurring infections persisted, targeted sequencing of the PID associated *activation-induced cytidine deaminase (AID)* and *uracil DNA glycosylase (UNG)* genes was carried out, but revealed no mutations.

Patient P2, a girl, was born to a consanguineous family of Arab origin. At the age of 5, she developed sudden onset of nasal bleedings. Complete blood count showed low platelet numbers and she was treated for immune thrombocytopenia with multiple courses of IVIG and steroids. At the age of 7, she developed recurrent chest infections with symptoms of malabsorption clinically diagnosed as cystic fibrosis. Sweat chloride tests showed a chloride level of 46 mmol/L. However, no mutations in the *cystic fibrosis transmembrane conductance regulator* (*CFTR)* gene were found, while a chest computed tomography scan revealed bronchiectasis and pulmonary nodules. The patient also experienced two hemolytic episodes (Hgb: 2.9 g/dL) with a positive direct coombs test. At the age of 14, she presented again at our ward with hematolytic anemia (Hgb: 4.29 g/dL). General examination showed clubbing of the fingers, lymphadenopathy and hepatosplenomegaly. Immunological characterization revealed CD4 lymphopenia, increased level of DNTs (13.2%) and hypergammaglobulinemia leading to the initial clinical diagnosis of ALPS like disease ([@B19]). But in addition and not characteristic for ALPS like patients she presented with fulminant EBV infection. After discharge, the patient did not return to our ward and died at the age of 15.

To identify the underlying genetic cause of the disease whole exome sequencing was performed on peripheral blood mononuclear cells (PBMC) of the patients and their family members. Next generation sequencing and data analysis revealed that both patients harbored homozygous *STK4* mutations segregated from their heterozygous parents. Patient P1 carried a previously described single nucleotide deletion leading to early protein truncation \[c.1103 delT, p.M368RfsX2, ([@B2])\]. Patient P2 harbored a novel mutation at a splice donor site (c.525+2 T\>G). Pedigree analysis revealed that the patients were the only homozygous mutation carriers in their families (Figure [1A](#F1){ref-type="fig"}). *STK4* mutations described in patients are homozygous nonsense or frameshift mutations that occur across the whole coding sequence. The M368RfsX2 that leads to truncation before the SARAH domain is the most C terminal described so far. The SARAH domain of STK4 is involved in signal transduction and homodimerization of STK4. The mutation found in P2 is the first splice site mutation reported in this cohort (Figure [1B](#F1){ref-type="fig"}). Expression analysis of STK4 on mRNA and protein level showed a decrease of *STK4* transcript levels in both patients compared to healthy controls and an STK4 protein deficiency for patient P1 (Figure [1C](#F1){ref-type="fig"}, Supplemental Figures [1](#SM1){ref-type="supplementary-material"}, [2](#SM1){ref-type="supplementary-material"}). Due to scarcity of patient material and lack of transformed cells from patient P2, the effect of the mutation on protein level is unclear. However, the mutation most likely leads to mis-splicing of STK4 within its kinase domain and any generated protein should be functionally deficient.

![STK4 mutations in two patients. **(A)** Left*:* Sanger sequencing using genomic DNA confirmed homozygous *STK4* mutations in Patient 1 (P1) and Patient 2 (P2). Representative chromatograms of a healthy control, the homozygous patients (P1/P2) and the heterozygous mothers (M1/M2) of each patient are shown. Right*:* Pedigrees of the two consanguineous families are presented. The patients are the only diseased members of the family and the only homozygous mutation carriers. **(B)** Schematic drawing of the STK4 protein. The protein harbors a kinase domain and a SARAH (Sav/Rassf/Hpo) domain that mediates signal transduction and homodimerization of STK4. Two caspase cleavage sites are described that lead to truncation of the protein before the SARAH domain similar to the M368RfsX2 mutation of P1. Mutations identified in our patients are presented in green, other previously reported mutations in black \[M368RfsX2, previously also described by ([@B2])\] ([@B2], [@B3], [@B4], [@B5], [@B6]). **(C)** Left*: STK4* transcript expression is reduced in both patients compared to healthy controls. Presented are levels of *STK4* mRNA expression in whole blood extracts relative to healthy controls assessed by qPCR. Expression was calculated as fold change compared to healthy control using the ΔΔCt method. GAPDH and β-actin expression were used as internal standards. A representative experiment of two is shown. Mean values of an experiment carried out in triplicates and corresponding standard deviations are shown. Right*:* STK4 protein deficiency is analyzed in patient derived transformed T cells of patient 1 and primary cells of patient 2. STK4 protein levels were analyzed by western blot. β-actin was used as a control. Total protein levels of P2 are low due to scarcity of primary patient material.](fimmu-09-02400-g0001){#F1}

Functional analysis of primary patient derived cells from P1 showed a phenotype of impaired T cell proliferation (Figure [2A](#F2){ref-type="fig"}) and dysregulated gene expression of FOXO1, IL/RA, and BCL2 (Figure [2B](#F2){ref-type="fig"}). Transformed T cells derived from patient P1 showed increased susceptibility to apoptosis induced by kinase inhibitor staurosporine or serum withdrawal compared to healthy controls (Figure [2C](#F2){ref-type="fig"}). Not typical for ALPS like disease, these cells showed no defect of apoptosis induced via the Fas death receptor pathway (Supplemental Figure [3](#SM1){ref-type="supplementary-material"}).

![STK4 deficiency results in defective proliferation, gene dysregulation and increased susceptibility to apoptosis. **(A)** Proliferation is defective in STK4 deficient primary cells. Upper*:* Peripheral blood mononuclear cells of patient P1 and a healthy control were treated with the indicated lymphocyte activating compounds. Relative proliferation was quantified by ^3^H thymidine uptake (measured in counts per minute per 2 × 10^5^ cells) after 72 h. A representative experiment of two is shown. Relative values are given compared to a healthy control (HC, = 1). Mean values of triplicates and corresponding standard deviations are shown. Lower*:* Primary T cells of patient P1 and a healthy control were activated with PHA and cultivated in the presence of IL2. Viable cells were determined by trypan blue staining and counted with a Neubauer chamber. **(B)** STK4 deficiency dysregulates gene expression. Expression of target genes was determined in whole blood from patient P1 relative to healthy controls (dotted line). Expression was calculated as fold change compared to a healthy control using the ΔΔCt method. GAPDH and β-actin expression were used as internal standards. A representative experiment of two is shown. Mean values of an experiment carried out in triplicates and corresponding standard deviations are shown. **(C)** STK4 deficient T cells have a significantly increased apoptosis susceptibility in response to staurosporine or serum starvation compared to healthy control T cells. Primary T cells of patient P1 and a healthy control were stimulated with 0.5 μM staurosporine for 16 h or serum starved for 2 days or left untreated. Apoptosis was analyzed by flow cytometric measurement of Annexin V-FITC and PI staining. Relative apoptosis is presented compared to untreated controls. A representative experiment of two is shown. Mean values of an experiment carried out in duplicates and corresponding standard deviations are shown. \**p* \< 0.05.](fimmu-09-02400-g0002){#F2}

To investigate whether lacking or reduced *STK4* expression is a general trait of lymphomas, we analyzed the expression of STK4 in publicly available datasets of 201 healthy tissues and 1,675 lymphomas available in the R2: Genomics Analysis and Visualization Platform (<http://r2.amc.nl>). We found that STK4 was significantly downregulated in all lymphoma datasets compared to healthy datasets indicating a tumor suppressive role of STK4 (Supplemental Figure [4](#SM1){ref-type="supplementary-material"}, Supplemental Table [1](#SM1){ref-type="supplementary-material"}).

During further follow up patient P1 developed another EBV negative neoplasm, a Hodgkin lymphoma, at the age of 15 years. She received anti-CD20 monoclonal antibody rituximab and chemotherapy, but after one block of OEPA induction therapy (prednisone, doxorubicin, vincristine and etoposide as recommended by the EuroNet-PhL-C2 protocol) she experienced an infection or reactivation of Varicella zoster virus (VZV or human herpesvirus 3, HHV-3) and developed clinical herpes zoster with paraparesis and osteonecrosis of the legs. After treatment with cyclophosphamide and IVIG the neurological situation improved. Consolidation treatment with two modified COPDAC blocks (typically a combination of prednisone, vincristine, cyclophosphamide, and dacarbazine) was modified here by omission of prednisone and vincristine because of osteonecrosis and the neurologic situation. After achieving complete remission she received an allogeneic stem cell transplant from her HLA-matched sister. At the time of manuscript preparation, a few weeks after transplantation, she is tumor free and in good condition.

Discussion {#s4}
==========

Homozygous *STK4* mutations have been described in PID patients presenting with CD4 lymphopenia and recurring infections ([@B1]--[@B6]). Here, we report on two additional patients with STK4 deficiency, one of them (P2) harboring the first homozygous splice site mutation (c.525+2 T\>G) described in this patient entity and the other carrying a previously reported homozygous frameshift mutation (P1; c.1103 delT, p.M368RfsX2) (Table [1](#T1){ref-type="table"}) ([@B2]). The initial clinical picture of these two cases resembled the phenotype of ALPS like syndromes (lymphadenopathy, increased numbers of DNT cells). This was more exlicit in the case of patient P2 who presented with classical clinical ALPS symptoms including lymphadenopathy, hepatosplenomegaly, highly elevated DNT cell number (13.2%), hemolytic anemia, and hypergammaglobulinemia. However, further clinical work up showed that, not typical for ALPS patients, these symptoms were associated with malignant disease at early age in patient P1 and with EBV infection in patient P2.

###### 

Clinical and immunological characteristics of the patients.

                                **P1**                                                                                                                                                                                                                                                                       **P2**                                                                                                                                       **Reference values**
  ----------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ----------------------
  STK4 mutation                 c.1103 delT, p.M368RfsX2                                                                                                                                                                                                                                                     c.525+2 T\>G                                                                                                                                 
  Age at first presentation     10                                                                                                                                                                                                                                                                           5                                                                                                                                            
  Sex                           Female                                                                                                                                                                                                                                                                       Female                                                                                                                                       
  Hematology                    Lymphadenopathy, CD4 lymphopenia, elevated DNT cell number, dysregulated Ig levels, increased Vitamin B12                                                                                                                                                                    Lymphadenopathy, hepatosplenomegaly, elevated DNT cell number, CD4 lymphopenia, thrombocytopenia, hemolytic anemia, hypergammaglobulinemia   
  Infection                     Recurring otitis, VZV/HHV3 infection/reactivation during chemotherapy, negative for CMV, EBV, HHV6, HSV1, and HSV2                                                                                                                                                           Recurrent chest infections, active EBV infection                                                                                             
  Other clinical findings       B cell lymphoma, Hodgkin lymphoma, pulmonary valve stenosis, polyarthritis                                                                                                                                                                                                   Nasal bleedings, bronchiectasis and pulmonary nodules, clubbing of the fingers                                                               
  Treatment                     1st lymphoma: NHL-BFM 04 protocol (risk group 2), additional CC block (risk group 3, dosis reduced to 80%), 2nd lymphoma: rituximab and chemotherapy: one OEPA and two modified COPDAC blocks, allogeneic hematopoietic stem cell transplantation of matched sibling donor   IVIG, steroids                                                                                                                               
  **IMMUNOLOGICAL PHENOTYPE**                                                                                                                                                                                                                                                                                                                                                                                                                             
  Leukocytes/μL                 7400                                                                                                                                                                                                                                                                         na                                                                                                                                           4.1--8.3 × 1000/ μL
  Lymphocytes \[%\]             6                                                                                                                                                                                                                                                                            25                                                                                                                                           34.5--48.2
  Lymphocytes absolute          444                                                                                                                                                                                                                                                                          na                                                                                                                                           1.0--5.3 × 1000/μL
  CD3+ \[%\]                    71                                                                                                                                                                                                                                                                           80                                                                                                                                           52--78
  CD3+CD4+\[%\]                 10                                                                                                                                                                                                                                                                           18                                                                                                                                           25--48
  CD3+CD8+\[%\]                 50                                                                                                                                                                                                                                                                           50                                                                                                                                           9.0--35
  CD45RA+CD4+\[%\]              30                                                                                                                                                                                                                                                                           na                                                                                                                                           49.3--72
  CD45RO+CD4+\[%\]              70                                                                                                                                                                                                                                                                           na                                                                                                                                           24.5--44.4
  CD45RA+CD8+\[%\]              48                                                                                                                                                                                                                                                                           na                                                                                                                                           62.3--86.3
  CD45RO+CD8+ \[%\]             52                                                                                                                                                                                                                                                                           na                                                                                                                                           12.2--27.2
  TCRαβ+CD4-CD8-\[%\]           3.7                                                                                                                                                                                                                                                                          13.2                                                                                                                                         \< 2
  CD45+CD127+ (IL7RA) \[%\]     8.7                                                                                                                                                                                                                                                                          na                                                                                                                                           65.8--89.6
  CD20+ \[%\]                   12                                                                                                                                                                                                                                                                           na                                                                                                                                           9.1--21
  IgD+CD27-\[%\]                86                                                                                                                                                                                                                                                                           na                                                                                                                                           9.1--21
  IgD+CD27+\[%\]                6                                                                                                                                                                                                                                                                            na                                                                                                                                           0.85--2.53
  IgD-CD27+ \[%\]               2.4                                                                                                                                                                                                                                                                          na                                                                                                                                           4.1--18.7
  CD3-CD56 + \[%\]              19.7                                                                                                                                                                                                                                                                         3                                                                                                                                            6.0--27
  IgG \[mg/dL\]                 147                                                                                                                                                                                                                                                                          1814                                                                                                                                         572--1474
  IgA \[mg/dL\]                 504                                                                                                                                                                                                                                                                          486                                                                                                                                          34--305
  IgM \[mg/dL\]                 752                                                                                                                                                                                                                                                                          33                                                                                                                                           31--208
  Vitamin B12 \[pg/mL\]         \>2000                                                                                                                                                                                                                                                                       na                                                                                                                                           197--866

*Cell surface markers were measured and analyzed by flow cytometry on a FACSCalibur using CellQuest software (Becton Dickinson Biosciences, Heidelberg, Germany). Immunoglobulins (Ig) were measured in the serum by ELISA. \[CMV, Cytomegalovirus; DNT, double negative T cells; EBV, Epstein Barr virus; HHV3, human herpes virus 3; HHV6, human herpes virus 6; IVIG, intravenous immunoglobulins; NHL-BFM, Non-Hodgkin Lymphoma-Berlin-Frankfurt-Münster, VZV, varicella zoster virus (synonymous for HHV3)\]*.

The cohort of STK4 deficient patients is highly susceptible to EBV infections. Eight of 15 reported cases so far presented with persistent EBV viremia and five of 15 developed EBV associated lymphoproliferative disorders, primarily affecting B cells (Table [2](#T2){ref-type="table"}). The impact of active EBV infections on lymphoma development is well-established ([@B20]). Therefore, similar to other related disorders associated with EBV infections (such as MAGT1 or ITK deficiency), the lymphoma incidence in STK4 deficient patients is assumed to be increased although the absolute number of reported cases, including the case presented here is still low (*n* = 3). Sherkat et al. reported on a patient who presented first with a B cell lymphoproliferative syndrome and developed later an EBV+ primary cardiac T cell lymphoma, a very rare pediatric malignancy ([@B1], [@B6]). Nehme et al. reported on a case who suffered from an EBV+ Hodgkin B cell lymphoma ([@B2]). The patient P1 presented here harbored the same mutation as described by Nehme et al. and developed two independent lymphomas in the course of follow up: an aggressive B cell lymphoma and a Hodgkin lymphoma. Strikingly, both lymphomas were negative for EBV tested in blood, liquor and tumor biopsies. A hit-and-run mechanism of virus infection seems therefore unlikely. This strongly suggests a cancer predisposition mechanism of STK4 mutations independent of EBV infections.

###### 

Lymphoproliferation and malignancies reported so far in STK4 deficient patients.

  **Patient- No**.   **Persistent EBV viraemia**   **Lymphoproliferation/malignancy**                                     **References**
  ------------------ ----------------------------- ---------------------------------------------------------------------- ----------------
  1                  Negative                                                                                             ([@B1])
  2                  Negative                                                                                             ([@B1])
  3                  Positive                      B-lymphoproliferative syndrome/ EBV+ primary cardiac T-cell lymphoma   ([@B1], [@B6])
  4                  Positive                      EBV+ Hodgkin B-cell lymphoma                                           ([@B2])
  5                  Positive                      B-lymphoproliferative syndrome                                         ([@B2])
  6                  Positive                                                                                             ([@B2])
  7                  Negative                                                                                             ([@B2])
  8                  Negative                                                                                             ([@B3])
  9                  Negative                                                                                             ([@B4])
  10                 Negative                                                                                             ([@B4])
  11                 Positive                      Lymphoproliferative syndrome                                           ([@B5])
  12                 Positive                      Lymphoproliferative syndrome                                           ([@B5])
  13                 Positive                                                                                             ([@B5])
  14                 Negative                      EBV-B-cell lymphoma and Hodgkin lymphoma                               Present study
  15                 Positive                      Lymphoproliferative syndrome                                           Present study

The potential role of STK4 in tumorigenesis was investigated in various studies in mice. Conditional knockout of the mouse gene homolog *Mst1* in intestine or liver resulted in the generation of solid tumors at these sites ([@B21], [@B22]). Pathogenic upregulation of the Hippo signaling pathway was revealed as the tumor driver. Kim et al. ([@B15]) reported that *Mst1* knockout mice were prone to leukemia and lymphoma development after mutagen treatment or p53 deletion. Lymphomagenesis was not driven by hippo upregulation under these conditions, but by chromosomal instability. They analyzed publicly available microarray gene expression data of human acute lymphoblastic leukemia and various human lymphomas from the Oncomine database ([www.oncomine.org](http://www.oncomine.org)) that showed a downregulation of *STK4* in these entities. In the present study, we analyzed publicly available datasets of 201 healthy tissues and 1,675 lymphomas available in the R2 platform. We could confirm a significant general downregulation of *STK4* in lymphomas derived from B- T- and NK cells. The mechanisms of STK4 in lymphoma suppression still need to be clarified and will most likely be complex due to the multiple essential functions of STK4 in e.g. apoptosis, autophagy, chromosome stability, cell cycle progression. A perturbed B cell function is indicated by reduced B cell numbers and hypogammaglobulinemia in some STK4 deficient patients. In addition, Dang et al. demonstrated impaired adhesive response to chemokines in patient-derived EBV transformed B cells ([@B5]). However, a comprehensive analysis of STK4 deficient B cell function is still lacking. Our own *in vitro* analyses confirmed the effect of STK4 deficiency on lymphocyte function and gene expression established in the previous works.

A perturbed immune surveillance due to CD4 lymphopenia has to be taken into account as an EBV independent mechanism that may promote lymphoma development. In this line, approximately 20% of patients with idiopathic CD4 lymphopenia also develop malignancies, lymphoma being the most common one. EBV infections were remarkably uncommon in this patient entity (\~ 2%) ([@B23]). A similar cohort with CD4 lymphopenia is presented by patients with HIV infections. The risk of lymphoma in HIV patients is increased 60--200 fold for non-Hodgkin lymphoma and 8--10 fold for classical Hodgkin lymphoma compared to the healthy population ([@B24]).

Our data suggests that patients with STK4 deficiency should be under close lymphoma surveillance even in the absence of EBV infections. In addition, a possibly underlying STK4 deficiency should be suspected and tested in patients with a clinical history of recurrent infections, CD4 lymphopenia and lymphoma and unknown genetic make-up.
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